Transine Therapeutics, a Cambridge, UK-based biotechnology company, raised £13.7M in Seed funding.
The round was led by Epidarex Capital with participation from Dementia Discovery Fund (DDF). Mary Canning, Principal at Epidarex Capital, has joined Transine’s Board following this financing.
The company intends to use the funds to further exploit its SINEUP® platform and accelerate the development of its product portfolio, building on recent advances with its lead programs in Central Nervous System and Ophthalmology indications with key in vivo data expected this year.
Founded by Professor Piero Carninci and Professor Stefano Gustincich, pioneers in functional genomics and lncRNA, and based in Cambridge, UK, and led by CEO Dr Jan Thirkettle, Transine Therapeutics is an RNA platform company developing a novel class of therapeutic RNAs (SINEUPs) capable of upregulating protein expression with a level of control and specificity across a high range of diseases and applications. Conceived to boost the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation, their SINEUP platform allows us to address diseases which, until now, have been beyond the reach of small molecules, conventional biologics or gene therapies.